PTK2 and neoplasm: Although the pro-vascular effect from recruited BMDCs has been implicated in both tumor protection and disease relapse [48,49], the augmentation of anti-angiogenic activity due to the addition of vinorelbine to sorafenib can potentially be attributed to the downregulation of the FAK signaling pathway, which contributed to the improved tumor response.